NCT06513624View on ClinicalTrials.gov

ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 9, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
Interventions
DRUG

ETC-159

ETC-159 will be administered orally.

DRUG

Pembrolizumab

Pembrolizumab will be administered intravenously.

DRUG

Denosumab / Zoledronic Acid

Denosumab will be administrated subcutaneously. Zoledronic Acid will be administered intravenously if denosumab has no response.

Trial Locations (2)

Singapore 169610

NOT_YET_RECRUITING

National Cancer Centre Singapore, Singapore

Unknown

RECRUITING

National University Hospital, Singapore

All Listed Sponsors
collaborator

EDDC (Experimental Drug Development Centre), A*STAR Research Entities

OTHER_GOV

lead

National University Hospital, Singapore

OTHER